The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001226392p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
18/09/2026
Date registered
Help: Date registered
7/10/2026
Date last updated
Help: Date last updated
7/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
7/10/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
The effectiveness of ultrasound-guided supraclavicular block for closed reduction of upper extremity injuries in the emergency department compared to procedural sedation
Scientific title
SUPraclavicular block vs procedural sedation for the Emergency Reduction of upper limB injuries (SUPERB II): a multisite open-label randomised controlled trial
Additional trial identifiers [1] 318485 0
Nil knnown
Universal Trial Number (UTN)
Trial acronym
SUPERB II
Related trial records

Health condition
Health condition(s) studied:
Distal radius fracture 343659 0
Distal ulnar fracture 343731 0
Condition category
Condition code
Emergency medicine 339771 339771 0 0
Other emergency care
Anaesthesiology 339772 339772 0 0
Other anaesthesiology
Injuries and Accidents 339849 339849 0 0
Fractures
Musculoskeletal 339850 339850 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Ultrasound-guided supraclavicular block (UGSCB)
To perform UGSCB, the participant will be in a semi-reclined position with head turned from the side to be blocked. Participants will be monitored with continuous pulse oximetry, five minutely blood pressure on the unaffected limb and 5-lead ECG. Aseptic technique will be adhered to including sterile gloves, ultrasound probe cover and sterile gel. Following informed consent, the skin will be prepared with chlorhexidine and draped. A Sonosite X-Porte ultrasound (Fujifilm) with a 12 MHz linear probe (or equivalent) will be placed over the supraclavicular fossa to identify the brachial plexus. A 22 G echogenic needle (Sonoplex, Pajunk) attached to a 20 ml syringe will be inserted under ultrasound guidance to deposit 20 ml consisting of 5 ml 1% lignocaine/adrenaline and 15 ml 0.75% ropivacaine, with 10 ml deposited at the lower trunk (between lower trunk and first rib, i.e., “corner pocket”) and 10 ml deposited between the upper and middle trunks. The mixture of short-acting (1% lignocaine/adrenaline) and long-acting local anaesthetic (0.75% ropivacaine) ensures rapid onset of regional anaesthesia with prolonged analgesic effect. Adequacy of regional anaesthesia will be assessed by the treating clinician prior to closed reduction and immobilisation of the injured arm. The intervention will take approximately 20 min duration,, but the exact procedural time will be recorded by the research investigator or treating clinician in the case report form.

ED clinicians performing UGSCB for the trial will need to obtain a minimum standard of training or experience as deemed by the trial leads. Clinicians will include emergency physicians (i.e., FACEM’s) and ACEM advanced trainees. Those interested in the trial will be invited to undertake a training session (~60 min) which includes learning the anatomy, identification of major landmarks with ultrasound and performing simulated injections on phantoms. Clinicians will be required to perform at least three supervised UGSCB to be deemed independent. We anticipate a period of three months will be required, prior to the commencement of the trial.

The procedure will be performed on patients that require emergency closed reduction of the fracture or dislocation at the time of their presentation to the emergency department. This allows for re-alignment of the injured part such that the patient can be safely discharged home for orthopaedic review in 1-2 weeks time. Upon this review, the orthopaedic team will decide on conservative vs surgical management. Any patients requiring immediate surgical intervention at the time of emergency department presentation will be excluded from the study.
Intervention code [1] 335386 0
Treatment: Other
Description of the comparator or control
Procedural sedation (PS)
PS is a core skill for emergency physicians and will be performed by or under the supervision of an ED consultant as per local departmental protocol. This will be undertaken in a resuscitation cubicle with appropriate staffing. Monitoring will include continuous pulse oximetry, five-minutely blood pressure on the unaffected limb and cardiac monitoring with 5-lead ECG. Pre-oxygenation will occur with supplemental oxygen. Intravenous (IV) access will be obtained and the choice and dose of analgesic (eg, fentanyl) and sedation agents (propofol or ketamine) will be given at the discretion of the ED consultant to ensure tolerance to closed reduction. After IV sedation and completion of closed reduction, participants will be monitored until full recovery, including returning to baseline level of consciousness and stable haemodynamics, prior to discharge. We will record the type and dose of IV analgesia and anaesthetic for each participant. We anticipate the intervention will take approximately 20 min in duration but the exact procedural time will be recorded by the research investigator or treating cliinician in the case report form.
Control group
Active

Outcomes
Primary outcome [1] 346940 0
Primary outcome will be post-procedural pain intensity.
Timepoint [1] 346940 0
This will be assessed at 30 min post-closed reduction, or if a participant takes longer than 30 min to recover from PS, we will assess the primary outcome when a participant is deemed to be back to baseline level of consciousness and note the additional time. Previous studies demonstrate that median time to return to baseline mental status after PS was 14 min for IV ketamine and 5 min for IV propofol 16. Thus we anticipate that most participants will be assessable at 30 min.
Secondary outcome [1] 468190 0
Participant reported pain at 1-hour post-procedure
Timepoint [1] 468190 0
At 1-hour following closed reduction or prior to ED discharge (if <1-hour)
Secondary outcome [2] 468191 0
Participant satisfaction at 1-hour post-procedure
Timepoint [2] 468191 0
At 1-hour post-closed reduction (or prior to ED discharge if <1-hour)
Secondary outcome [3] 468192 0
Opioid use
Timepoint [3] 468192 0
From ambulance service until time of discharge from ED
Secondary outcome [4] 468193 0
Adverse events/complications
Timepoint [4] 468193 0
From the initation of the intervention (UGSCB or PS) until time of discharge from ED
Secondary outcome [5] 468194 0
Intervention failure
Timepoint [5] 468194 0
At time of discharge from the emergency department
Secondary outcome [6] 468195 0
ED LOS
Timepoint [6] 468195 0
From ED triage to discharge from ED
Secondary outcome [7] 468196 0
Procedural time
Timepoint [7] 468196 0
From the initiation of UGSCB or PS to completion of the closed reduction and plaster immobilisation.
Secondary outcome [8] 468197 0
Clinician satisfaction
Timepoint [8] 468197 0
Post-intervention completion
Secondary outcome [9] 468198 0
Post-procedural time
Timepoint [9] 468198 0
At the time of discharge from ED
Secondary outcome [10] 468199 0
Post-discharge pain VAS
Timepoint [10] 468199 0
Once between 24-72 hours post-discharge from ED
Secondary outcome [11] 468200 0
Patient satisfaction on a VAS after discharge from ED
Timepoint [11] 468200 0
Once between 24-72 hours post-discharge from ED
Secondary outcome [12] 468203 0
adverse events
Timepoint [12] 468203 0
Once between 24-72 hours post-discharge from ED
Secondary outcome [13] 468204 0
total opioid use in the first 24 hours post-discharge
Timepoint [13] 468204 0
Once between 24-72 hours post-discharge from ED
Secondary outcome [14] 468205 0
Quality of recovery after the intervention
Timepoint [14] 468205 0
Once between 24-72 hours post-discharge from ED
Secondary outcome [15] 468206 0
Cost-minimisation analysis
Timepoint [15] 468206 0
At the end of data collection for the trial

Eligibility
Key inclusion criteria
• Aged 18 years or above
• Can provide informed consent
• Present with radius and/or ulna fractures and/or dislocations that require closed reduction and immobilisation in ED and are amenable to UGSCB or PS. Participants will also be included if they failed previous reduction with conservative methods including inhaled nitrous oxide sedation.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Unable to consent
• Open fractures, unstable fracture or dislocations with/without neurovascular compromise that require urgent surgical fixation
• Pregnant

Specific contraindications to UGSCB include:
• Hypersensitivity to local anaesthetic
• Chronic lung disease (e.g., unstable asthma or chronic obstructive pulmonary disease)
• Skin infection over supraclavicular fossa
• Previous surgery or radiation to supraclavicular region
• Injection of local anaesthetic as part of previous reduction attempt including Bier block or haematoma block, due to increased risk of local anaesthetic systemic toxicity (LAST).

Specific contraindications for PS include:
• Anticipated difficult airway as assessed by the treating clinician that is better suited for anaesthesia in the operating theatre
• Hypersensitivity to anaesthetic medication
• Respiratory distress or chronic lung disease
• Haemodynamic instability with systolic BP equal to or less than 90 mmHg
• Evidence of intoxication

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants will be randomised in a 1:1 allocation ratio using stratified block randomisation with variable block sizes of 4 and 6 to maintain balance across intervention groups. Randomisation will be stratified by trial site and conducted securely via the online Griffith Randomisation Service (https://randomisation.griffith.edu.au/). As this is an open-label RCT, there will be no blinding of the research investigator, clinicians or participants.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Block randomisation will be performed in 1:1 ratio in random blocks of size 4-6 (size randomly selected) to ensure equal numbers in each group
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Data will be summarised as mean (SD) or median (interquartile range [IQR]) for continuous variables, depending on normality of their distribution, and as frequency (percentage) for categorical variables. Tests of noninferiority will employ one-sided significance testing with type I error rate of 0.025; other tests will be two-sided with alpha of 0.05. The primary outcome (pain VAS at 30 minutes post-closed reduction) will be analysed using Wilcoxon rank-sum test for noninferiority, with PS group scores shifted by the noninferiority margin of 1.3 cm prior to comparison, consistent with the approach used in the SUPERB trial. Linear regression will also be performed and the upper bound of the 95% CI for the between-group difference compared to the noninferiority margin. Adjusted analyses will include trial site, baseline pain, age and sex as covariates.

Primary analysis will be conducted on intention-to-treat population; per-protocol analysis will also be performed and reported alongside, in keeping with Consolidated Stnadards of Reporting Trials (CONSORT) recommendations for noninferiority trials. If noninferiority is established for the primary outcome, a hierarchical superiority test for ED length of stay will be conducted using a generalised linear model with gamma family and log link, reflecting the anticipated right-skewed but strictly positive distribution of LOS data. Other continuous secondary outcomes will be analysed using linear regression, gamma GLM (for strictly positive skewed outcomes such as procedural time and post-procedural time) or median regression (for skewed outcomes that may include zeros, such as opioid use) as appropriate. Repeated measures outcomes (pain VAS, participant satisfaction at follow-up) will be analysed using linear mixed models. Dichotomous outcomes will be analysed using logistic regression. Secondary outcomes will be analysed without adjustment for multiplicity and will be interpreted as hypothesis-generating. Missing data will be reported by treatment group; complete case analysis will be performed if missing data is less than 5%; otherwise, multiple imputation will be performed. Statistical analysis will be performed on Stata (StataCorp).

A power calculation was performed for the primary outcome of post-procedural pain intensity for closed reduction of radius ± ulna fractures. From our SUPERB trial raw data, the standard deviation (SD) of pain VAS was 2.6 cm for UGSCB 11. Assuming an equal SD in the PS group, a non-inferiority margin of 1.3 cm (the minimum clinically important difference for VAS pain established by Gallagher et al 20), one-sided alpha of 0.025, 80% power, and a true between-group difference of zero, 63 participants per group (126 total) are required. Allowing for 10% attrition and to satisfy block randomisation multiples across four sites (using variable block sizes of 4 and 6), we aim to recruit at least 144 participants with distal radius and/or ulna fracture requiring closed reduction across the four trial sites.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 30241 0
Redland Hospital - Cleveland
Recruitment hospital [2] 30242 0
Caboolture Hospital - Caboolture
Recruitment hospital [3] 30243 0
John Hunter Hospital - New Lambton
Recruitment hospital [4] 30244 0
Royal Brisbane & Womens Hospital - Herston
Recruitment postcode(s) [1] 46639 0
4163 - Cleveland
Recruitment postcode(s) [2] 46640 0
4510 - Caboolture
Recruitment postcode(s) [3] 46641 0
2305 - New Lambton
Recruitment postcode(s) [4] 46642 0
4029 - Herston

Funding & Sponsors
Funding source category [1] 323061 0
Charities/Societies/Foundations
Name [1] 323061 0
Emergency Medicine Foundation
Country [1] 323061 0
Australia
Primary sponsor type
Government body
Name
Metro South Health Service
Address
Country
Australia
Secondary sponsor category [1] 326004 0
None
Name [1] 326004 0
Address [1] 326004 0
Country [1] 326004 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 321461 0
Metro South Human Research Ethics Committee
Ethics committee address [1] 321461 0
Ethics committee country [1] 321461 0
Australia
Date submitted for ethics approval [1] 321461 0
16/09/2026
Approval date [1] 321461 0
Ethics approval number [1] 321461 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153802 0
Dr Henry Tsao
Address 153802 0
Redland Hospital, 21 Weippin Street, Cleveland, Queensland, Australia 4163
Country 153802 0
Australia
Phone 153802 0
+61 402054279
Fax 153802 0
Email 153802 0
Contact person for public queries
Name 153803 0
Henry Tsao
Address 153803 0
Redland Hospital, 21 Weippin Street, Cleveland, Qld, Australia, 4163
Country 153803 0
Australia
Phone 153803 0
+61 7 34883111
Fax 153803 0
Email 153803 0
Contact person for scientific queries
Name 153804 0
Henry Tsao
Address 153804 0
Redland Hospital, 21 Weippin Street, Cleveland, Qld, Australia, 4163
Country 153804 0
Australia
Phone 153804 0
+61 7 34883111
Fax 153804 0
Email 153804 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• The data can be made available to researchers upon reasonable request and this will be on a case-by-case basis at discretion.

Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
When can requests for individual participant data be made (start and end dates)?
From:
At the end of the study
To:
A finite period of: 15 years
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: Access to the data will be subject to approval by the principal investigator and Metro South Research. Please contact the principal investigator on [email protected] or Metro South Health Research on [email protected].

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
ProtocolNo This is the study protocol as submitted to the MSH... [More Details] SUPERB 2 RCT HREC protocol v1.0.docx

Documents added automatically
No additional documents have been identified.